Osteopontin expression in oral lichen planus

Journal of Oral Pathology and Medicine

Volumn 37, Issue 2, 2008, Pages 94-98

  Zhou, Zeng Tong ^a,c   Wei, Ben Juan ^b   Shi, Peng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c 9th People's Hospital   (China)

Author keywords

Oral lichen planus; Osteopontin; Transforming growth factor 1; Tumour necrosis factor

Indexed keywords

OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUTH DISEASE; MOUTH LICHEN PLANUS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LICHEN PLANUS, ORAL; MALE; MIDDLE AGED; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38149118682     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2007.00599.x     Document Type: Article

References (28)

1. Khan A, Farah CS, Savage NW, et al. Th1 cytokines in oral lichen planus. J Oral Pathol Med 2003 32 : 77 83.
2. Bagan Sebastian JV, Milian Masanet MA, Penarrocha Diago M, et al. A clinical study of 205 patients with oral lichen planus. J Oral Maxillofac Surg 1992 50 : 116 8.
3. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000 287 : 860 4.
4. O'Regan AW, Nau GJ, Chupp GL, et al. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 2000 21 : 475 8.
5. Weber GF, Ashkar S, Glimcher MJ, et al. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996 271 : 509 12.
6. Agnihotri R, Crawford HC, Haro H, et al. Osteopontin, a novel substrate for matrix metalloproteinase-3(stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001 276 : 28261 7.
7. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem Suppl 1998 31 : 92 102.
8. Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001 107 : 1055 61.
9. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell mediated and granulomatous inflammation. Int J Exp Pathol 2000 81 : 373 90.
10. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 2001 41 : 723 49.
11. Begum MD, Umemura M, Kon S, et al. Suppression of the bacterial antigen-specific T cell response and the dendritic cell migration to the lymph nodes by osteopontin. Microbiol Immunol 2007 51 : 135 47.
12. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001 294 : 1731 5.
13. Sakata M, Tsuruha JI, Masuko-Hongo K, et al. Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 2001 28 : 1492 5.
14. Chiocchetti A, Indelicato M, Bensi T, et al. High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lympho-proliferation. Blood 2004 103 : 1376 82.
15. Miklos S, Gruschwitz MS. In situ expression and serum levels of tumor necrosis factor alpha receptors in patients with lichen planus. Acta Derm Venereol 1997 77 : 191 3.
16. Sklavounou A, Chrysomali E, Iakovou M, et al. Elevated serum levels of the apoptosis related molecules TNF-α, Fas/Apo-1 and Bcl-2 in oral lichen planus. J Oral Pathol Med 2004 33 : 386 90.
17. Xu G, Nie H, Li N, et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 2005 115 : 1060 7.
18. Amatschek S, Koenig U, Auer H, et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 2004 64 : 844 56.
19. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002 13 : 350 65.
20. O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-γ and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 2000 68 : 495 502.
21. Masutani K, Akahoshi M, Tsuruya K, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001 44 : 2097 106.
22. Katagiri Y, Mori K, Hara T, et al. Functional analysis of the osteopontin molecule. Ann N Y Acad Sci 1995 760 : 371 4.
23. Ohshima S, Yamaguchi N, Nishioka K, et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 2002 29 : 2061 7.
24. Dang H, Geiser AG, Letterio JJ, et al. SLE-like autoantibodies and Sjögren's syndrome-like lymphoproliferation in TGF-beta knockout mice. J Immunol 1995 155 : 3205 12.
25. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992 359 : 693 9.
26. Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 1999 18 : 1280 91.
27. Strober W, Kelsall B, Fuss I, et al. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today 1997 18 : 61 4.
28. Thompson NL, Flanders KC, Smith JM, et al. Expression of transforming growth factor-ß1 in specific cells and tissues of adult and neonatal mice. J Cell Biol 1989 108 : 661 9.